Gapping down
In reaction to earnings/guidance:
- ACB -2.7%, CURO -0.6%
Other news:
- ALT -20.3% (results from 12-week Phase 1 clinical trial of ALT-801)
- ZIOP -15.1% (will conduct strategic restructuring to extend TCR program cash runway into 1H23)
- BKD -8.1% (announces $200 mln convertible note offering)
- BNTX -4.6% (BioNTech and Pfizer submit data to from pivotal trial of COVID-19 Vaccine in children 5 to <12 years of age; seems to be sell the news reaaction)
- MEG -3.6% (stock offering)
- MANU -3% (files mixed securities shelf offering)
- NOVA -2% (announces partnership with AutoGrid)
Analyst comments:
- ASML -5.2% (downgraded to Neutral from Buy at New Street)
- AMAT -3.8% (downgraded to Neutral from Buy at New Street)
- MCHP -3% (downgraded to Equal Weight from Overweight at Wells Fargo)
- WFC -1% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- MS -0.9% (downgraded to Hold from Buy at Berenberg)